What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Veit L. Buecklein, Ludwig-Maximilians-Universitat, Munich, DE. We asked, What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?

Buecklein begins by discussing findings from a real-world analysis comparing progression-free survival, overall survival, response rates, toxicity, and non-relapse mortality in EU vs US patients with DLBCL after CAR T-cell therapy. Buecklein then outlines possible reasons for these differences, including the adverse risk-profiles of patients, availability of product types, and time between treatment and CAR T-cell infusion for different indications.